Abstract
After vaccinating health care workers and vulnerable groups against COVID-19, authorities will need to decide how to vaccinate everyone else. Prioritising individuals with more contacts can be disproportionately effective, in theory, but identifying these individuals is difficult. Here we show that the technology underlying Bluetooth exposure notification applications, such as used for digital contact tracing, can be leveraged to prioritise vaccination based on individual contact data. Our approach is based on the insight that these apps also act as local sensing devices measuring each user’s total exposure time to other users, thereby enabling the implementation of a previously impossible strategy that prioritises potential super-spreaders. Furthermore, by generalising percolation theory and introducing a novel measure of vaccination efficiency, we demonstrate that this “hot-spotting” strategy can achieve herd immunity with up to half as many vaccines as a non-targeted strategy, and is attractive even for relatively low rates of app usage.
Competing Interest Statement
EWT is an employee of Sanofi Pasteur. All authors are inventors of the US Provisional Patent Application No. 63/122,587.
Funding Statement
We acknowledge support from the National Sciences and Engineering Research Council of Canada (NSERC), NSERC COVID-19 Alliance Grant (MDP, MA, CTB) and Ontario Ministry of Colleges and Universities COVID-19 Rapid Response Grant (MA, CTB).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No approvals were needed for this work.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All source files for the simulations are available upon request.
